Article
Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
mAbs - 1 Jan 2000
Monnet Céline, Jorieux Sylvie, Souyris Nathalie, Zaki Ouafa, Jacquet Alexandra, Fournier Nathalie, Crozet Fabien, de Romeuf Christophe, Bouayadi Khalil, Urbain Rémi, Behrens Christian K, Mondon Philippe, Fontayne Alexandre
Abstract excerpt
While glyco-engineered monoclonal antibodies (mAbs) with improved antibody-dependent cell-mediated cytotoxicity (ADCC) are reaching the market, extensive efforts have also been made to improve their pharmacokinetic properties to generate biologically superior molecules. Most therapeutic mAbs are human or humanized IgG molecules whose half-life is dependent on the neonatal Fc receptor FcRn. FcRn reduces IgG...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.